Behind the revenue figures in the Bristol Myers Squibb Q3 2026 results sits a pipeline update with real scientific content: a first-in-class cancer drug with accelerated approval, an investigational lung-disease drug that met one dose’s endpoint but not another’s, and a radiopharmaceutical with a positive interim analysis. Bristol Myers Squibb reported third-quarter revenue of $13.1 billion, up 7%, and raised its 2026 revenue forecast, according to press reports. This article focuses on the clinical and regulatory developments, what each result does and does not show, and the data still to come.
Bristol Myers Squibb Q3 2026 results: the evidence in brief
- Zenbexus, described as the first CELMoD agent, received FDA accelerated approval in multiple myeloma; Phase 3 progression-free survival data are due at the ASH meeting in December.
- Mezigdomide, an investigational CELMoD, has an FDA target action date of 13 May 2027.
- Admilparant, an investigational drug, met its primary endpoint in idiopathic pulmonary fibrosis at 60 mg; the 120 mg dose was not statistically significant.
- RYZ101 had a positive Phase 3 interim analysis, and arlo-cel a positive Phase 2 result.
- Milvexian and Sotyktu lupus data are expected before the end of the year.
CELMoD agents in the Bristol Myers Squibb Q3 2026 results
CELMoD stands for cereblon E3 ligase modulating drug. These agents work by bringing certain proteins to the cell’s degradation machinery so that they are broken down, an approach that already underpins older medicines such as lenalidomide. According to the reports, Zenbexus is the first CELMoD to reach the market and has accelerated approval in multiple myeloma. Accelerated approval allows earlier access based on a surrogate endpoint, with confirmatory evidence required afterward, which is why the December Phase 3 progression-free survival data matter. We have not seen the label, so we do not describe its indication in detail. The FDA explains the pathway on its accelerated approval page.
Mezigdomide and the Bristol Myers Squibb Q3 2026 results
Mezigdomide is an investigational CELMoD and is not approved. The reports give a target action date of 13 May 2027 under the FDA’s review timetable, which is a goal and not a guarantee of approval. The sources do not detail the trial data supporting the filing, so we cannot assess the size of the benefit.
What the admilparant result shows in the Bristol Myers Squibb Q3 2026 results
Idiopathic pulmonary fibrosis is a progressive scarring lung disease. Reports say admilparant met its primary endpoint at the 60 mg dose, but the 120 mg dose did not reach statistical significance. That pattern can arise when higher doses add little benefit, when the trial is not powered to separate the doses or by chance. The sources do not give the endpoint, effect size or safety data, and the drug is investigational. Readers should wait for the full presentation before drawing conclusions.
Why dose-response patterns matter in the Bristol Myers Squibb Q3 2026 results
In many drugs, a higher dose produces a larger effect up to a plateau, and sometimes more side effects. A result where the middle dose works and the higher one does not is unusual enough that regulators and clinicians will look closely at the data: Were patient groups balanced? Did more people stop the higher dose because of adverse events? Is there a biological reason for a plateau? These are generic questions of trial interpretation and not findings about admilparant, since the sources contain none of the underlying numbers.
Radiopharmaceuticals and cell therapy in the Bristol Myers Squibb Q3 2026 results
RYZ101, from the radiopharmaceutical company RayzeBio, had a positive Phase 3 interim analysis, according to the reports. Interim analyses can stop trials early but carry a risk of overestimating effects, so the final data will matter. Arlo-cel, a cell therapy, showed positive Phase 2 results. Breyanzi, an approved cell therapy, reached $526 million in sales, up 48%. For background on the company’s work in India, see our report on Bristol Myers Squibb in India.
The commercial backdrop to the Bristol Myers Squibb Q3 2026 results
Revenue of $13.1 billion included Growth Portfolio sales of $7.7 billion, up 12%, and Legacy Portfolio sales of $5.4 billion, up 1%. Non-GAAP earnings per share were $1.35, down 17%, after a $1.6 billion acquired research charge. Reports on 2026 earnings guidance conflict on direction, and we could not reach a primary release. Company information is at bms.com.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s Cancer Therapeutics Market report values the global market at USD 193.7 billion in 2024 and projects USD 381.5 billion by 2033, a CAGR of 7.9% for 2025 to 2033. North America was the largest region at USD 71.7 billion in 2024, and Asia Pacific is projected to grow fastest at 8.8% a year. The report was published in April 2025, so it predates these results and covers oncology only. See our Pharmaceutical section.
Timeline of the Bristol Myers Squibb Q3 2026 results pipeline
- Late October 2026: third-quarter results and pipeline update.
- December 2026: Zenbexus Phase 3 data at ASH.
- 13 May 2027: mezigdomide target action date.
General background: surrogate endpoints and accelerated approval
A surrogate endpoint is a measure expected to predict clinical benefit, such as tumour response. Accelerated approval relies on it so patients can access promising medicines sooner, with confirmatory trials needed later. Outcomes of those trials can confirm, narrow or withdraw an approval.
Our analysis of the Bristol Myers Squibb Q3 2026 results
In our assessment, the Bristol Myers Squibb Q3 2026 results contain several clinically meaningful signals, but most depend on data not yet public: the Phase 3 survival data for Zenbexus, the details behind admilparant’s dose result and the final RYZ101 findings.
What is not disclosed in the Bristol Myers Squibb Q3 2026 results
- Efficacy and safety figures for admilparant and mezigdomide.
- Full RYZ101 interim results.
- Zenbexus label details.
Risks and caveats
This article relies on press reports and does not include trial publications. Investigational drugs are not approved for the uses described. It is news reporting and not medical or investment advice.
What to watch next
- ASH presentations in December.
- Milvexian and Sotyktu lupus data.
- FDA action on mezigdomide.
FAQ
What is a CELMoD?
A drug class that directs specific proteins for degradation inside cells.
Is mezigdomide approved?
No, it is investigational.
Did admilparant work?
It met its primary endpoint at 60 mg but not at 120 mg, per reports.
How we reported this: we relied on press reports of the results, public company and regulator pages and the Acumen Research and Consulting report cited above. We did not have a primary company release. Last updated 30 October 2026. This is news reporting and not advice.
